The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Insights on menin inhibition and emerging strategies to improve response and MRD outcomes in AML
In this video, Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses the latest data on menin inhibition in acute leukemias, particularly in acute myeloid leukemia (AML), and its impact on depth of response, durability, and measurable residual disease (MRD). Dr Patel notes that while menin inhibitors have shown significant promise in the relapsed/refractory (R/R) setting, the majority of patients do not respond to single-agent menin inhibition, and ongoing studies are investigating the addition of these agents to frontline regimens. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
